In breaking news, the US Food and Drug Administration has approved donanemab, a monoclonal antibody developed by Eli Lilly to address early symptomatic Alzheimer’s disease. This antibody aims to slow the progression of the disease by aiding in the removal of amyloid plaque buildup in the brain, a key characteristic of Alzheimer’s. The drug, to be marketed as Kisunla, is priced at $695 per vial or $12,522 for a six-month course, and around $32,000 for a full year. Stay tuned for updates on this developing story.
